Treat to target in weight management with semaglutide: Real‐world evidence from an eHealth clinic
Authors' conclusion
Participants achieved clinically meaningful weight loss comparable to that seen in randomised trials, despite using lower semaglutide doses. These findings support the effectiveness of a personalised, treat-to-target approach integrating medical and behavioural obesity management in a digital setting.
Study context
- Population
- Danish adults living with overweight or obesity enrolled in a digital weight loss programme via the Embla app, January 2022–September 2024; 78% women, mean age 46.8 ± 10.8 years, mean BMI 34.3 ± 4.8465 remaining at week 64
- Participants
- 2,694 adults
- Outcome
- Percentage change in body weight
- Follow-up
- Week 64
Methodological detailssingle-group, digital (eHealth) programme, Participants remaining at weeks 26, 52 and 64: 1580, 712 and 465
- Single-group
- Digital (eHealth) programme
- Participants remaining at weeks 26, 52 and 64: 1580, 712 and 465
Main finding
As reported in the abstract
Mean weight loss at week 64
16.7%
95% CI −17.4 to −16.0
Observational data: associations, not effects.
Secondary outcomes
Semaglutide dose · week 64
- Mean semaglutide dose
- 1.08 mg/week (SD 0.54)
Proportions achieving ≥5% and ≥10% weight loss
- Achieved ≥5% weight loss
- 98%
- Achieved ≥10% weight loss
- 82%
Weight change by baseline BMI and dose
- Weight change was consistent across BMI classes and medication doses
Original publication
Treat to target in weight management with semaglutide: Real‐world evidence from an eHealth clinic. Diabetes Obes Metab. Published 3 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →